Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | BACE1 | P56817 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 8/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283657 | 0.98 | KDM4E (0.74) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL26985810 | 0.87 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL30831555 | 0.87 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL109617 | 0.86 | LTA4H (0.59) | KDM4EALDH1A1SMN1; SMN2LTA4HTSHR | |
| SCHEMBL6932153 | 0.85 | KDM4E (0.72) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL14970709 | 0.85 | KDM4E (0.97) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL13766268 | 0.85 | KDM4E (0.97) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL224640 | 0.84 | PSMB1 (0.76) | LTA4HPSMB1PSMB5PSMB2 | |
| Hydrochloric Acid SCHEMBL14966569 | 0.84 | KDM4E (0.94) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H | |
| SCHEMBL305458 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2BACE1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ROCK1, ROCK2, RHOA | KDM4E 1119/4885ALDH1A1 3461/4885SMN1; SMN2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.